Invivyd Stock
Invivyd, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marc William Elia
- Employees
- 122
- Market cap
- $182 M
- IPO
- 06/08/2021
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing…
Invivyd stock: price history
1D
-7.5%
1W
-14.2%
1M
-23.2%
6M
-64.4%
YTD
-75.0%
1Y
-64.7%
2Y
-37.2%
5Y
-98.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~24% weaker price swings than usual
Ask the agents about Invivyd
Analyst assessment of Invivyd
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.50
MEDIAN
US$9.50
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
5
BUY
3
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 14/09/2026
Invivyd stock metrics
P/E
-1.57
P/B
1.09
EV/EBITDA
-0.29
RETURN ON EQUITY
-24.5%
NET MARGIN
-310.8%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.8%
FLOAT SHARES
261,669,060
AVG. DAILY VOLUME (30D)
6,316,309
Insider transactions (SEC)
Allen Robert D. III
Allen Robert D. III
Allen Robert D. III
Andersen Jill
Andersen Jill
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.5%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Invivyd stock
What does Invivyd do?
Invivyd, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marc William Elia, the company employs around 122 people.
The IPO was on 06/08/2021; the stock trades on NASDAQ under the ticker IVVD.
What do analysts say about Invivyd stock?
8 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$9.50, ranging from US$9.00 to US$10.00, with a median of US$9.50.
This is an external assessment, not a statement by Market Jury.
When does Invivyd report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -24% stronger than usual.
Does Invivyd pay a dividend?
No, Invivyd currently does not pay a dividend.
Which stocks are comparable to Invivyd?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Invivyd stock analyzed?
Clicking "Analyze stock" lets five strategies assess Invivyd against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.